Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule

Objective: The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule....

Full description

Bibliographic Details
Main Authors: Totterdell, J.A., Chacon, G.P., Estcourt, M.J., Jones, M., Richmond, P., Snelling, Tom, Marsh, J.A.
Format: Journal Article
Published: 2022
Online Access:http://purl.org/au-research/grants/nhmrc/1158722
http://hdl.handle.net/20.500.11937/91407
_version_ 1848765513281306624
author Totterdell, J.A.
Chacon, G.P.
Estcourt, M.J.
Jones, M.
Richmond, P.
Snelling, Tom
Marsh, J.A.
author_facet Totterdell, J.A.
Chacon, G.P.
Estcourt, M.J.
Jones, M.
Richmond, P.
Snelling, Tom
Marsh, J.A.
author_sort Totterdell, J.A.
building Curtin Institutional Repository
collection Online Access
description Objective: The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule. Participants: Up to 3000 Australian infants 6 to <12 weeks of age born ≥32 weeks gestation. Interventions: The intervention is a wP containing vaccine as the first scheduled pertussis vaccine dose instead of an aP containing vaccine. Outcomes: The primary outcome is a binary indicator of history of IgE-mediated food allergy at the age of 12 months confirmed, where necessary, with an oral food challenge before 18 months of age. Secondary outcomes include (1) history of parent-reported clinician-diagnosed new onset of atopic dermatitis by 6 or 12 months of age with a positive skin prick test to any allergen before 12 months of age, (2) geometric mean concentration in pertussis toxin-specific IgG before and 21 to 35 days after a booster dose of aP at 18 months of age, and (3) sensitisation to at least one allergen by 12 months of age. Results: Operating characteristics of trial decision rules were evaluated by trial simulation. The selected rules for success and futility approximately maintain type I error of 0.05 and achieved power 0.85 for a reduction in the primary outcome from 10% in the control group to 7% in the intervention group. Discussion: A detailed, prospective statistical analysis plan (SAP) is presented for this Bayesian adaptive design. The plan was written by the trial statistician and details the study design, pre-specified adaptive elements, decision thresholds, statistical methods, and the simulations used to evaluate the operating characteristics of the trial. Application of this SAP will minimise bias and supports transparent and reproducible research. Trial registration: Australia & New Zealand Clinical Trials Registry, ACTRN12617000065392. Registered on 12 January 2017 Study protocol: https://doi.org/10.1136/bmjopen-2020-042838
first_indexed 2025-11-14T11:36:27Z
format Journal Article
id curtin-20.500.11937-91407
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T11:36:27Z
publishDate 2022
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-914072023-08-23T02:42:37Z Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule Totterdell, J.A. Chacon, G.P. Estcourt, M.J. Jones, M. Richmond, P. Snelling, Tom Marsh, J.A. Objective: The purpose of this double-blind, randomised, controlled trial is to compare allergic outcomes in children following vaccination with acellular pertussis (aP) antigen (standard of care in Australia) given at 2 months of age versus whole cell pertussis (wP) in the infant vaccine schedule. Participants: Up to 3000 Australian infants 6 to <12 weeks of age born ≥32 weeks gestation. Interventions: The intervention is a wP containing vaccine as the first scheduled pertussis vaccine dose instead of an aP containing vaccine. Outcomes: The primary outcome is a binary indicator of history of IgE-mediated food allergy at the age of 12 months confirmed, where necessary, with an oral food challenge before 18 months of age. Secondary outcomes include (1) history of parent-reported clinician-diagnosed new onset of atopic dermatitis by 6 or 12 months of age with a positive skin prick test to any allergen before 12 months of age, (2) geometric mean concentration in pertussis toxin-specific IgG before and 21 to 35 days after a booster dose of aP at 18 months of age, and (3) sensitisation to at least one allergen by 12 months of age. Results: Operating characteristics of trial decision rules were evaluated by trial simulation. The selected rules for success and futility approximately maintain type I error of 0.05 and achieved power 0.85 for a reduction in the primary outcome from 10% in the control group to 7% in the intervention group. Discussion: A detailed, prospective statistical analysis plan (SAP) is presented for this Bayesian adaptive design. The plan was written by the trial statistician and details the study design, pre-specified adaptive elements, decision thresholds, statistical methods, and the simulations used to evaluate the operating characteristics of the trial. Application of this SAP will minimise bias and supports transparent and reproducible research. Trial registration: Australia & New Zealand Clinical Trials Registry, ACTRN12617000065392. Registered on 12 January 2017 Study protocol: https://doi.org/10.1136/bmjopen-2020-042838 2022 Journal Article http://hdl.handle.net/20.500.11937/91407 10.1186/s13063-021-05874-6 http://purl.org/au-research/grants/nhmrc/1158722 http://creativecommons.org/licenses/by/4.0/ fulltext
spellingShingle Totterdell, J.A.
Chacon, G.P.
Estcourt, M.J.
Jones, M.
Richmond, P.
Snelling, Tom
Marsh, J.A.
Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
title Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
title_full Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
title_fullStr Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
title_full_unstemmed Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
title_short Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
title_sort statistical analysis plan for the optimum study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule
url http://purl.org/au-research/grants/nhmrc/1158722
http://hdl.handle.net/20.500.11937/91407